{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:30Z","timestamp":1784808090606,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hyperthermic intraperitoneal chemotherapy (HIPEC) has been proven to improve the survival rate of gastric cancer and reduce peritoneal recurrence. We aimed to evaluate the effectiveness and safety of prophylactic HIPEC after radical gastric cancer surgery in this study. Researchers searched for studies published in PubMed, Embase, Web of science, Scopus, Cochrane, Clinical key databases and Microsoft Academic databases to identify studies that examine the impact of prophylactic HIPEC on the survival, recurrence and adverse events of patients undergoing radical gastric cancer surgery. RevMan 5.3 was used to analyze the results and risk of bias. The PROSERO registration number is CRD42021262016. This meta-analysis included 22 studies with a total of 2097 patients, 12 of which are RCTs. The results showed that the 1-, 3- and 5-year overall survival rate was significantly favorable to HIPEC (OR 5.10, 2.07, 1.96 respectively). Compared with the control group, the overall recurrence rate and peritoneal recurrence rate of the HIPEC group were significantly lower (OR 0.41, 0.24 respectively). Significantly favorable to the control group in terms of renal dysfunction and pulmonary dysfunction complications (OR 2.44, 6.03 respectively). Regarding the causes of death due to postoperative recurrence: liver recurrence, lymph node and local recurrence and peritoneal recurrence, the overall effect is not significantly different (OR 0.81, 1.19, 0.37 respectively). 1-, 3- and 5-year overall survival follow-up may be incremented by the prophylactic HIPEC, and which reduce the overall recurrence rate and peritoneal recurrence rate. HIPEC may have high-risk of pulmonary dysfunction and renal dysfunction complications. No difference has been found in the deaths due to recurrence after surgery.<\/jats:p>","DOI":"10.1038\/s41598-022-06417-y","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T11:03:04Z","timestamp":1645009384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prophylactic hyperthermic intraperitoneal chemotherapy may benefit the long-term survival of patients after radical gastric cancer surgery"],"prefix":"10.1038","volume":"12","author":[{"given":"Xuhui","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuewen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"6417_CR1","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska, J., Baj, J., Sitarz, M., Maciejewski, R. & Sitarz, R. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int. J. Mol. Sci. 21, 4012 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"6417_CR2","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.3748\/wjg.v22.i17.4307","volume":"22","author":"M Mihmanli","year":"2016","unstructured":"Mihmanli, M., Ilhan, E., Idiz, U. O., Alemdar, A. & Demir, U. Recent developments and innovations in gastric cancer. World J. Gastroenterol. 22, 4307\u20134320 (2016).","journal-title":"World J. Gastroenterol."},{"key":"6417_CR3","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.3748\/wjg.v20.i16.4483","volume":"20","author":"R Rahman","year":"2014","unstructured":"Rahman, R., Asombang, A. W. & Ibdah, J. A. Characteristics of gastric cancer in Asia. World J. Gastroenterol. 20, 4483\u20134490 (2014).","journal-title":"World J. Gastroenterol."},{"key":"6417_CR4","doi-asserted-by":"publisher","first-page":"205873922094233","DOI":"10.1177\/2058739220942339","volume":"18","author":"X Liu","year":"2020","unstructured":"Liu, X. & Tang, M. Effect of early body cavity continuous circulation hyperthermia perfusion chemotherapy combined with systemic chemotherapy (and nursing) on survival rate and serum tumor markers in patients with advanced gastric cancer. Eur. J. Inflamm. 18, 2058739220942339 (2020).","journal-title":"Eur. J. Inflamm."},{"key":"6417_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3748\/wjg.v12.i3.372","volume":"12","author":"R Swan","year":"2006","unstructured":"Swan, R. & Miner, T. J. Current role of surgical therapy in gastric cancer. World J. Gastroenterol. 12, 372\u2013379 (2006).","journal-title":"World J. Gastroenterol."},{"key":"6417_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen, I. et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int. J. Cancer. 134, 622\u2013628 (2014).","journal-title":"Int. J. Cancer."},{"key":"6417_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto, S. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med. 357, 1810\u20131820 (2007).","journal-title":"N. Engl. J. Med."},{"key":"6417_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11\u201320 (2006).","journal-title":"N. Engl. J. Med."},{"key":"6417_CR9","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","volume":"288","author":"MF Flessner","year":"2005","unstructured":"Flessner, M. F. The transport barrier in intraperitoneal therapy. Am. J. Physiol. Ren. Physiol. 288, F433\u2013F442 (2005).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"6417_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet, P. & Sugarbaker, P. H. Peritoneal-plasma barrier. Cancer Treat. Res. 82, 53\u201363 (1996).","journal-title":"Cancer Treat. Res."},{"key":"6417_CR11","first-page":"1","volume":"62","author":"RL Dedrick","year":"1978","unstructured":"Dedrick, R. L., Myers, C. E., Bungay, P. M. & DeVita, V. T. Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1\u201311 (1978).","journal-title":"Cancer Treat. Rep."},{"key":"6417_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.addr.2020.02.004","volume":"163\u2013164","author":"ALB Seynhaeve","year":"2020","unstructured":"Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C. & Ten Hagen, T. L. M. Hyperthermia and smart drug delivery systems for solid tumor therapy. Adv. Drug Deliv. Rev. 163\u2013164, 125\u2013144 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"6417_CR13","first-page":"295","volume":"26","author":"T Hehr","year":"2003","unstructured":"Hehr, T., Wust, P., Bamberg, M. & Budach, W. Current and potential role of thermoradiotherapy for solid tumours. Onkologie 26, 295\u2013302 (2003).","journal-title":"Onkologie"},{"key":"6417_CR14","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3748\/wjg.v22.i3.1114","volume":"22","author":"RA Seshadri","year":"2016","unstructured":"Seshadri, R. A. & Glehen, O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J. Gastroenterol. 22, 1114\u20131130 (2016).","journal-title":"World J. Gastroenterol."},{"key":"6417_CR15","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan, T. D. et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann. Surg. Oncol. 14, 2702\u20132713 (2007).","journal-title":"Ann. Surg. Oncol."},{"key":"6417_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim, K. et al. Methodological index for non-randomized studies (minors): Development and validation of a new instrument. ANZ J. Surg. 73, 712\u2013716 (2003).","journal-title":"ANZ J. Surg."},{"key":"6417_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/SLA.0b013e31824682f4","volume":"255","author":"EF Vinuela","year":"2012","unstructured":"Vinuela, E. F., Gonen, M., Brennan, M. F., Coit, D. G. & Strong, V. E. Laparoscopic versus open distal gastrectomy for gastric cancer: A meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann. Surg. 255, 446\u2013456 (2012).","journal-title":"Ann. Surg."},{"key":"6417_CR18","first-page":"1510","volume":"21","author":"L-Z Gao","year":"2016","unstructured":"Gao, L.-Z. et al. Hyperthermic intraperitoneal chemotherapy plus high-frequency diathermic therapy followed by intravenous chemotherapy versus intravenous chemotherapy alone for postoperative adjuvant treatment of gastrointestinal cancer: A comparative research study. J. B.U.ON. 21, 1510\u20131517 (2016).","journal-title":"J. B.U.ON."},{"key":"6417_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.gassur.2003.12.014","volume":"8","author":"JJ Hall","year":"2004","unstructured":"Hall, J. J. et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J. Gastrointest. Surg. 8, 454\u2013463 (2004).","journal-title":"J. Gastrointest. Surg."},{"key":"6417_CR20","volume":"98","author":"HW Zhang","year":"2019","unstructured":"Zhang, H. W. et al. Postoperative intraperitoneal hyperthermic perfusion improve survival for advanced gastric cancer. Medicine (United States). 98, e16598 (2019).","journal-title":"Medicine (United States)."},{"key":"6417_CR21","first-page":"2168","volume":"29","author":"H Akiyama","year":"2002","unstructured":"Akiyama, H. et al. Effectiveness of continuous hyperthermic peritoneal perfusion for the peritoneal dissemination of gastric cancer. Gan To Kagaku Ryoho 29, 2168\u20132173 (2002).","journal-title":"Gan To Kagaku Ryoho"},{"key":"6417_CR22","first-page":"1436","volume":"25","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi, K., Fujimoto, S., Takahashi, M., Muto, T. & Toyosawa, T. Clinical result of intraperitoneal hyperthermic chemoperfusion for gastric cancer with serosal invasion to prevent peritoneal recurrence. Gan To Kagaku Ryoho 25, 1436\u20131438 (1998).","journal-title":"Gan To Kagaku Ryoho"},{"key":"6417_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07339-6","volume":"20","author":"L Zhu","year":"2020","unstructured":"Zhu, L. et al. Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: A retrospective clinical study. BMC Cancer 20, 1\u20139 (2020).","journal-title":"BMC Cancer"},{"key":"6417_CR24","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.2147\/CMAR.S249838","volume":"12","author":"Y Zhong","year":"2020","unstructured":"Zhong, Y. et al. Lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer: Safety and efficacy profiles. Cancer Manag. Res. 12, 5141\u20135146 (2020).","journal-title":"Cancer Manag. Res."},{"key":"6417_CR25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4251\/wjgo.v12.i7.782","volume":"12","author":"TY Xie","year":"2020","unstructured":"Xie, T. Y. et al. Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer. World J. Gastrointest. Oncol. 12, 782\u2013790 (2020).","journal-title":"World J. Gastrointest. Oncol."},{"key":"6417_CR26","doi-asserted-by":"publisher","first-page":"205873922094233","DOI":"10.1177\/2058739220942339","volume":"18","author":"X Liu","year":"2020","unstructured":"Liu, X. & Tang, M. Effect of early body cavity continuous circulation hyperthermia perfusion chemotherapy combined with systemic chemotherapy (and nursing) on survival rate and serum tumor markers in patients with advanced gastric cancer. Eur. J. Inflamm. 18, 205873922094233 (2020).","journal-title":"Eur. J. Inflamm."},{"key":"6417_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12885-021-07925-2","volume":"21","author":"B Fan","year":"2021","unstructured":"Fan, B. et al. Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer 21, 216 (2021).","journal-title":"BMC Cancer"},{"key":"6417_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3892\/etm.2014.1599","volume":"7","author":"HB Cui","year":"2014","unstructured":"Cui, H. B. et al. Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer. Exp. Ther. Med. 7, 1083\u20131088 (2014).","journal-title":"Exp. Ther. Med."},{"key":"6417_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1186\/s12885-019-6125-z","volume":"19","author":"MK Beeharry","year":"2019","unstructured":"Beeharry, M. K. et al. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: Personal experience from a randomized case control study. BMC Cancer 19, 932 (2019).","journal-title":"BMC Cancer"},{"key":"6417_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jcma.2013.04.004","volume":"76","author":"LY Kang","year":"2013","unstructured":"Kang, L. Y. et al. Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. J. Chin. Med. Assoc. 76, 425\u2013431 (2013).","journal-title":"J. Chin. Med. Assoc."},{"key":"6417_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/BF00299188","volume":"19","author":"Y Yonemura","year":"1995","unstructured":"Yonemura, Y. et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J. Surg. 19, 450\u2013455 (1995).","journal-title":"World J. Surg."},{"key":"6417_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U","volume":"61","author":"S Koga","year":"1988","unstructured":"Koga, S. et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61, 232\u2013237 (1988).","journal-title":"Cancer"},{"key":"6417_CR33","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q","volume":"73","author":"R Hamazoe","year":"1994","unstructured":"Hamazoe, R., Maeta, M. & Kaibara, N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73, 2048\u20132052 (1994).","journal-title":"Cancer"},{"key":"6417_CR34","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00348209","volume":"18","author":"T Fujimura","year":"1994","unstructured":"Fujimura, T. et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: Randomized controlled study. World J. Surg. 18, 150\u2013155 (1994).","journal-title":"World J. Surg."},{"key":"6417_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9","volume":"85","author":"S Fujimoto","year":"1999","unstructured":"Fujimoto, S., Takahashi, M., Mutou, T., Kobayashi, K. & Toyosawa, T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 85, 529\u2013534 (1999).","journal-title":"Cancer"},{"key":"6417_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000012016","volume":"57","author":"K Hirose","year":"1999","unstructured":"Hirose, K. et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: Evaluation by multivariate regression analysis. Oncology 57, 106\u2013114 (1999).","journal-title":"Oncology"},{"key":"6417_CR37","first-page":"581","volume":"161","author":"M Ikeguchi","year":"1995","unstructured":"Ikeguchi, M. et al. Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur. J. Surg. 161, 581\u2013586 (1995).","journal-title":"Eur. J. Surg."},{"key":"6417_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/BF00294724","volume":"19","author":"T Takahashi","year":"1995","unstructured":"Takahashi, T., Hagiwara, A., Shimotsuma, M., Sawai, K. & Yamaguchi, T. Prophylaxis and treatment of peritoneal carcinomatosis: Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. World J. Surg. 19, 565\u2013569 (1995).","journal-title":"World J. Surg."},{"key":"6417_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1067\/msy.2002.123769","volume":"131","author":"C Kunisaki","year":"2002","unstructured":"Kunisaki, C. et al. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery. 131, 521\u2013528 (2002).","journal-title":"Surgery."},{"key":"6417_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s101200100013","volume":"4","author":"JY Kim","year":"2001","unstructured":"Kim, J. Y. & Bae, H. S. A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer 4, 27\u201333 (2001).","journal-title":"Gastric Cancer"},{"key":"6417_CR41","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.ejso.2019.07.030","volume":"45","author":"MY Reutovich","year":"2019","unstructured":"Reutovich, M. Y., Krasko, O. V. & Sukonko, O. G. Hyperthermic intraperitoneal chemotherapy in serosa-invasive gastric cancer patients. Eur. J. Surg. Oncol. 45, 2405\u20132411 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"6417_CR42","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00423-021-02137-5","volume":"406","author":"F Rosa","year":"2021","unstructured":"Rosa, F. et al. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: Experience from a Western tertiary referral center. Langenbeck\u2019s Arch. Surg. 406, 1071\u20131080 (2021).","journal-title":"Langenbeck's Arch. Surg."},{"key":"6417_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/02656736.2014.893451","volume":"30","author":"RR Yarema","year":"2014","unstructured":"Yarema, R. R. et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study. Int. J. Hyperth. 30, 159\u2013165 (2014).","journal-title":"Int. J. Hyperth."},{"key":"6417_CR44","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/jso.25823","volume":"121","author":"TP Diniz","year":"2020","unstructured":"Diniz, T. P. et al. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis. J. Surg. Oncol. 121, 823\u2013832 (2020).","journal-title":"J. Surg. Oncol."},{"key":"6417_CR45","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell, B. et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann. Surg. Oncol. 28, 258\u2013264 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"6417_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio, J. et al. The 30-year experience\u2014A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur. J. Cancer 79, 1\u201314 (2017).","journal-title":"Eur. J. Cancer"},{"key":"6417_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5230\/jgc.2020.20.e15","volume":"20","author":"DKA Chia","year":"2020","unstructured":"Chia, D. K. A. & So, J. B. Y. Recent advances in intra-peritoneal chemotherapy for gastric cancer. J. Gastr. Cancer. 20, 115\u2013126 (2020).","journal-title":"J. Gastr. Cancer."},{"key":"6417_CR48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/1471-2407-12-526","volume":"12","author":"J Sun","year":"2012","unstructured":"Sun, J. et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC Cancer 12, 526 (2012).","journal-title":"BMC Cancer"},{"key":"6417_CR49","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/cancers11111662","volume":"11","author":"AC Gamboa","year":"2019","unstructured":"Gamboa, A. C. & Winer, J. H. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer. Cancers (Basel). 11, 1662 (2019).","journal-title":"Cancers (Basel)."},{"key":"6417_CR50","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/bjs.11588","volume":"107","author":"RT van der Kaaij","year":"2020","unstructured":"van der Kaaij, R. T. et al. Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results. Br. J. Surg. 107, 1520\u20131528 (2020).","journal-title":"Br. J. Surg."},{"key":"6417_CR51","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1080\/14737140.2019.1671189","volume":"19","author":"A Macri","year":"2019","unstructured":"Macri, A. & Morabito, F. The use of intraperitoneal chemotherapy for gastric malignancies. Expert. Rev. Anticancer Ther. 19, 879\u2013888 (2019).","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"6417_CR52","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1245\/s10434-020-08226-x","volume":"27","author":"M Blum Murphy","year":"2020","unstructured":"Blum Murphy, M. et al. Phase I trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology. Ann. Surg. Oncol. 27, 2806\u20132811 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"6417_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.critrevonc.2015.04.004","volume":"95","author":"HJ Braam","year":"2015","unstructured":"Braam, H. J. et al. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit. Rev. Oncol. Hematol. 95, 282\u2013296 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"6417_CR54","first-page":"912418","volume":"2014","author":"G Montori","year":"2014","unstructured":"Montori, G. et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: State of the art. Int. J. Surg. Oncol. 2014, 912418 (2014).","journal-title":"Int. J. Surg. Oncol."},{"key":"6417_CR55","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.22017","volume":"104","author":"RS Gill","year":"2011","unstructured":"Gill, R. S. et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality, and morbidity. J. Surg. Oncol. 104, 692\u2013698 (2011).","journal-title":"J. Surg. Oncol."},{"key":"6417_CR56","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1016\/j.suronc.2010.09.002","volume":"20","author":"F Roviello","year":"2011","unstructured":"Roviello, F. et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments. Surg. Oncol. 20, e38-54 (2011).","journal-title":"Surg. Oncol."},{"key":"6417_CR57","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang, X. J. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann. Surg. Oncol. 18, 1575\u20131581 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"6417_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/jso.23633","volume":"110","author":"U Rudloff","year":"2014","unstructured":"Rudloff, U. et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. J. Surg. Oncol. 110, 275\u2013284 (2014).","journal-title":"J. Surg. Oncol."},{"key":"6417_CR59","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/jso.26366","volume":"123","author":"WJ Koemans","year":"2021","unstructured":"Koemans, W. J. et al. Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial. J. Surg. Oncol. 123, 904\u2013910 (2021).","journal-title":"J. Surg. Oncol."},{"key":"6417_CR60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12957-020-01819-6","volume":"18","author":"MK Beeharry","year":"2020","unstructured":"Beeharry, M. K., Zhang, T. Q., Liu, W. T. & Gang, Z. Z. Optimization of perioperative approaches for advanced and late stages of gastric cancer: Clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World J. Surg. Oncol. 18, 51 (2020).","journal-title":"World J. Surg. Oncol."},{"key":"6417_CR61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini, F. et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur. J. Surg. Oncol. 40, 12\u201326 (2014).","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06417-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06417-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:39:46Z","timestamp":1700235586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-06417-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6417"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-06417-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"3 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2583"}}